The impact of long-term gonadotropin-releasing hormone analogue treatment on preclinical abortions in patients with severe endometriosis undergoing in vitro fertilization-embryo transfer

Plain-language guide to PMID 1740204 (1992): randomized controlled trial study of Triptorelin in 67 women, endometriosis.

Key Facts

PMID: 1740204
Journal: Fertility and sterility
Year: 1992
Study type: Randomized Controlled Trial
Authors: Dicker D et al. (5 authors)
DOI: 10.1016/s0015-0282(16)54906-1

What This Study Did, in Plain Language

What Was Tested

Researchers studied Triptorelin in the context of endometriosis in this randomized controlled trial publication.

To examine the relationship between endometriosis and preclinical abortions and to evaluate the effect of gonadotropin-releasing hormone analogue (GnRH-a) therapy on these pregnancies.

Who Took Part

The abstract describes 67 women taking part.

PubMed indexes the participants as adults, women only.

Of 67 women with severe endometriosis referred to them for in vitro fertilization-embryo transfer (IVF-ET), 32 underwent ovarian stimulation for oocyte retrieval with menotropins (protocol A), whereas the other 35 were admitted for the procedure after a 6-month period of hormonal suppression with a GnRH agonist (protocol B).

The clinical impact of the preclinical and clinical pregnancies in both treatment protocols were evaluated on the basis of oocyte classification and embryo quality score.

How the Study Was Run

The design is described as randomized.

Because people in this Triptorelin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The timeline in the abstract includes 6 months.

All patients were treated in their IVF Unit.

What Was Measured

Topics PubMed links to this paper include Abortion, Spontaneous, Embryo Transfer, Endometriosis, Fertilization in Vitro, Gonadotropin-Releasing Hormone, Pregnancy Complications and Pregnancy Outcome.

What This Means in Plain Language

The paper is a randomized study of Triptorelin in 67 women in people with endometriosis over 6 months.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 1992 (Fertility and sterility), a journal based in United States.

More context: the Triptorelin compound page, Endometriosis research.

Our Notes on the Compound

Triptorelin: A 10-amino-acid GnRH analog (Trelstar, Decapeptyl, Triptodur) used in prostate cancer, early puberty and fertility protocols.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.